Mechanisms Accounting for Fluoroquinolone Resistance in Escherichia coli Clinical Isolates
- 1 January 2009
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (1), 235-241
- https://doi.org/10.1128/aac.00665-08
Abstract
Fluoroquinolone MICs are increased through the acquisition of chromosomal mutations in the genes encoding gyrase ( gyrA and gyrB ) and topoisomerase IV ( parC and parE ), increased levels of the multidrug efflux pump AcrAB, and the plasmid-borne genes aac ( 6 ′)- Ib -cr and the qnr variants in Escherichia coli . In the accompanying report, we found that ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant E. coli clinical isolates were very high and widely varied (L. Becnel Boyd, M. J. Maynard, S. K. Morgan-Linnell, L. B. Horton, R. Sucgang, R. J. Hamill, J. Rojo Jimenez, J. Versalovic, D. Steffen, and L. Zechiedrich, Antimicrob. Agents Chemother. 53: 229-234, 2009). Here, we sequenced gyrA , gyrB , parC , and parE ; screened for aac ( 6 ′)- Ib -cr and qnrA ; and quantified AcrA levels in E. coli isolates for which patient sex, age, location, and site of infection were known. We found that (i) all fluoroquinolone-resistant isolates had gyrA mutations; (ii) ∼85% of gyrA mutants also had parC mutations; (iii) the ciprofloxacin and norfloxacin MICs for isolates harboring aac ( 6 ′)- Ib -cr (∼23%) were significantly higher, but the gatifloxacin and levofloxacin MICs were not; (iv) no isolate had qnrA ; and (v) ∼33% of the fluoroquinolone-resistant isolates had increased AcrA levels. Increased AcrA correlated with nonsusceptibility to the fluoroquinolones but did not correlate with nonsusceptibility to any other antimicrobial agents reported from hospital antibiograms. Known mechanisms accounted for the fluoroquinolone MICs of 50 to 70% of the isolates; the remaining included isolates for which the MICs were up to 1,500-fold higher than expected. Thus, additional, unknown fluoroquinolone resistance mechanisms must be present in some clinical isolates.Keywords
This publication has 29 references indexed in Scilit:
- Relationships among Ciprofloxacin, Gatifloxacin, Levofloxacin, and Norfloxacin MICs for Fluoroquinolone-Resistant Escherichia coli Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2009
- Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and locationBMC Infectious Diseases, 2008
- Contributions of the Combined Effects of Topoisomerase Mutations toward Fluoroquinolone Resistance in Escherichia coliAntimicrobial Agents and Chemotherapy, 2007
- Prevalence in the United States of aac(6 ′ ) - Ib - cr Encoding a Ciprofloxacin-Modifying EnzymeAntimicrobial Agents and Chemotherapy, 2006
- The worldwide emergence of plasmid-mediated quinolone resistanceThe Lancet Infectious Diseases, 2006
- The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targetsJournal of Antimicrobial Chemotherapy, 2006
- qnrB , Another Plasmid-Mediated Gene for Quinolone ResistanceAntimicrobial Agents and Chemotherapy, 2006
- Induction and Inhibition of Ciprofloxacin Resistance-Conferring Mutations in Hypermutator BacteriaAntimicrobial Agents and Chemotherapy, 2006
- Inhibition of Mutation and Combating the Evolution of Antibiotic ResistancePLoS Biology, 2005
- Genetic Characterization of Highly Fluoroquinolone-Resistant Clinical Escherichia coli Strains from China: Role of acrR MutationsAntimicrobial Agents and Chemotherapy, 2001